Document is current
Any future updates will be listed below
-
Authors
Palandri, F. https://orcid.org/0000-0001-8367-5668
Auteri, G.
Abruzzese, E.
Caocci, G.
Bonifacio, M.
Mendicino, F.
Latagliata, R.
Iurlo, A.
Branzanti, F.
Garibaldi, B.
Trawinska, M. M.
Cattaneo, D.
Krampera, M.
Mulas, O.
Martino, E. A.
Cavo, M.
Vianelli, N.
Impera, S.
Efficace, F.
Heidel, F.
Breccia, M.
Elli, E. M.
Palumbo, G. A.
-
Funding
Funding for this research was provided by:
Ministero della Salute (RC-2023-2778963)
Alma Mater Studiorum - Università di Bologna
- License Information
-
More Information
Article History
Received: 27 November 2023
Accepted: 9 March 2024
First Online: 13 March 2024
Declarations
:
: Fr. Pa. consultancy and honoraria from AbbVie, Amgen, AOP, BMS Celgene, Novartis, CTI, GlaxoSmithKline, Grifols, Karyopharm, Morphosys, Sierra Oncology, Sobi; G.A.P. honoraria from Abbvie, AOP, AstraZeneca, BMS Celgene, Novartis, Incyte, Jannsen, Takeda; A. Iu., M.Br. and M. Bo. honoraria from Novartis, BMS, Pfizer, Incyte; M. Kr honoraria from Novartis, Amgen; F.H.H. consultancy for Novartis, CTI and Celgene and research funding from Novartis; M. Ca acted as consultant and received honoraria from Jannsen, BMS Celgene, SanoFI, GlaxoSmithKline, Takeda, Amgen, Oncopeptides, AbbVie, Karyopharm, and Adaptive; F. Ef. consultancy for AbbVie, Incyte, Syros and Novartis outside the submitted work.
